每周一次紫杉醇单药化疗作为一线顺铂治疗后尿路上皮膀胱癌的疗效。
Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.
作者信息
Sideris Spyridon, Aoun Fouad, Zanaty Marc, Martinez Nieves Chanza, Latifyan Sofia, Awada Ahmad, Gil Thierry
机构信息
Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium.
Department of Urology, Jules Bordet Institute, 1000 Brussels, Belgium.
出版信息
Mol Clin Oncol. 2016 Jun;4(6):1063-1067. doi: 10.3892/mco.2016.821. Epub 2016 Mar 17.
Abstract
The aim of the present study was to investigate the efficacy of paclitaxel following a first-line cisplatin regimen in patients with metastatic bladder cancer. The present study retrospectively evaluated the clinical effects and toxicities of second-line paclitaxel regimens following first-line cisplatin treatment in metastatic bladder cancer. A total of 42 patients with progressing metastatic urothelial bladder cancer following cisplatin-based chemotherapy were enrolled. The patients received weekly treatment with paclitaxel (80 mg/m) with a median duration of 3 months. The overall response rate, disease control rate and median progression free survival were 9.5, 45.2 and 6.4 months, respectively. Weekly paclitaxel was well-tolerated with rare grade III or IV toxicities. Second-line weekly paclitaxel treatment following first-line cisplatin-based chemotherapy is an effective and well-tolerated regimen in urothelial metastatic bladder cancer.
摘要
本研究的目的是调查紫杉醇在转移性膀胱癌患者一线顺铂治疗方案后的疗效。本研究回顾性评估了转移性膀胱癌患者一线顺铂治疗后二线紫杉醇方案的临床疗效和毒性。共有42例接受以顺铂为基础化疗后病情进展的转移性尿路上皮膀胱癌患者入组。患者接受每周一次的紫杉醇治疗（80mg/m），中位疗程为3个月。总缓解率、疾病控制率和中位无进展生存期分别为9.5%、45.2%和6.4个月。每周一次的紫杉醇耐受性良好，罕见III级或IV级毒性。一线顺铂为基础的化疗后二线每周一次的紫杉醇治疗是尿路上皮转移性膀胱癌的一种有效且耐受性良好的方案。
相似文献
1
Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.每周一次紫杉醇单药化疗作为一线顺铂治疗后尿路上皮膀胱癌的疗效。
Mol Clin Oncol. 2016 Jun;4(6):1063-1067. doi: 10.3892/mco.2016.821. Epub 2016 Mar 17.
2
Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.以顺铂为基础的化疗失败后，紫杉醇、异环磷酰胺和奈达铂二线化疗方案对转移性尿路上皮癌的临床意义。
Jpn J Clin Oncol. 2016 Aug;46(8):775-80. doi: 10.1093/jjco/hyw071. Epub 2016 Jun 6.
3
Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.晚期乳腺癌患者每周给予紫杉醇-顺铂联合粒细胞集落刺激因子支持治疗：一项II期研究。
Breast Cancer Res Treat. 1998 May;49(1):13-26. doi: 10.1023/a:1005945218155.
4
The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.紫杉醇在化疗敏感的泌尿生殖系统恶性肿瘤中的作用：膀胱癌和睾丸生殖细胞肿瘤的当前治疗策略
World J Urol. 1996;14(6):354-9. doi: 10.1007/BF00183114.
5
Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.每周使用紫杉醇、顺铂加持续输注高剂量5-氟尿嘧啶和亚叶酸钙治疗转移性尿路上皮癌的II期试验。
J Urol. 2007 Jan;177(1):84-9; discussion 89. doi: 10.1016/j.juro.2006.08.058.
6
Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.紫杉醇和顺铂化疗治疗铂类方案治疗失败后的转移性尿路上皮癌。
Int J Urol. 2011 May;18(5):350-7. doi: 10.1111/j.1442-2042.2011.02735.x. Epub 2011 Mar 1.
7
Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.Ⅲ类β-微管蛋白的表达可预测接受基于紫杉醇的二线化疗的顺铂耐药膀胱癌患者的预后。
Anticancer Res. 2018 Mar;38(3):1629-1635. doi: 10.21873/anticanres.12394.
8
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.每周一次紫杉醇联合24小时持续输注5-氟尿嘧啶、亚叶酸钙及每三周一次顺铂治疗晚期胃癌患者的II期研究
Anticancer Drugs. 2002 Jun;13(5):497-503. doi: 10.1097/00001813-200206000-00008.
9
A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.多西他赛每周给药作为转移性尿路上皮癌患者二线化疗的II期研究
Clin Genitourin Cancer. 2016 Feb;14(1):76-81. doi: 10.1016/j.clgc.2015.09.008. Epub 2015 Sep 25.
10
Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.每周剂量密集型紫杉醇和每三周低剂量顺铂：一线治疗晚期卵巢、输卵管和原发性腹膜癌的一种耐受性良好且有效的化疗方案。
Int J Environ Res Public Health. 2019 Nov 29;16(23):4794. doi: 10.3390/ijerph16234794.
引用本文的文献
1
The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-related genes in ovarian cancer.基于二硫键连接的细胞焦亡相关基因的分子亚型和免疫浸润特征在卵巢癌中的作用
Discov Oncol. 2024 Oct 28;15(1):596. doi: 10.1007/s12672-024-01489-w.
2
Role of disulfidptosis in colorectal adenocarcinoma: implications for prognosis and immunity.二硫键凋亡在结直肠腺癌中的作用：对预后和免疫的影响。
Front Immunol. 2024 Sep 27;15:1409149. doi: 10.3389/fimmu.2024.1409149. eCollection 2024.
3
Therapeutic and prognostic effect of disulfidptosis-related genes in lung adenocarcinoma.二硫键连接的细胞焦亡相关基因在肺腺癌中的治疗和预后作用
Heliyon. 2024 Jun 29;10(13):e33764. doi: 10.1016/j.heliyon.2024.e33764. eCollection 2024 Jul 15.
4
Disulfidptosis-related classification patterns and tumor microenvironment characterization in skin cutaneous melanoma.皮肤黑色素瘤中与二硫化物诱导的细胞程序性坏死相关的分类模式及肿瘤微环境特征
Melanoma Manag. 2024 Jan 12;10(2):MMT65. doi: 10.2217/mmt-2023-0006. eCollection 2023 Jun.
5
Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.利用机器学习识别的与二硫键凋亡相关的基因特征，预测低级别胶质瘤的临床结局、免疫异质性和潜在治疗靶点。
Front Immunol. 2023 Dec 15;14:1294459. doi: 10.3389/fimmu.2023.1294459. eCollection 2023.
6
Analysis of long non-coding RNAs associated with disulfidptosis for prognostic signature and immunotherapy response in uterine corpus endometrial carcinoma.分析与二硫键相关的长非编码 RNA 对子宫体子宫内膜癌的预后特征和免疫治疗反应的影响。
Sci Rep. 2023 Dec 14;13(1):22220. doi: 10.1038/s41598-023-49750-6.
7
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.伊布替尼联合疗法用于晚期尿路上皮癌的1b/2期研究结果。
Cancers (Basel). 2023 May 30;15(11):2978. doi: 10.3390/cancers15112978.
8
Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.基于机器学习生存框架的膀胱癌中二硫键相关亚型的串扰、预后特征模型的建立和免疫浸润特征分析。
Front Endocrinol (Lausanne). 2023 Apr 19;14:1180404. doi: 10.3389/fendo.2023.1180404. eCollection 2023.
9
Medical Image Diagnostic Value of Computed Tomography for Bladder Tumors.计算机断层扫描对膀胱癌的医学影像诊断价值。
Comput Math Methods Med. 2021 Nov 16;2021:3781028. doi: 10.1155/2021/3781028. eCollection 2021.
10
Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin.检查点抑制疗法进展后转移性尿路上皮癌的当前全身治疗选择——一项系统评价结合三项测试恩杂鲁胺的研究的单组荟萃分析
Cancers (Basel). 2021 Jun 26;13(13):3206. doi: 10.3390/cancers13133206.
本文引用的文献
1
Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy.中性粒细胞与淋巴细胞比值对行根治性膀胱切除术的膀胱癌患者的预后价值及新型术前风险分层模型的建立。
Urology. 2012 May;79(5):1085-91. doi: 10.1016/j.urology.2011.11.070. Epub 2012 Mar 23.
2
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.随机 III 期研究比较紫杉醇/顺铂/吉西他滨与吉西他滨/顺铂在未经系统治疗的局部晚期或转移性尿路上皮癌患者中的疗效：EORTC 协作组研究 30987。
J Clin Oncol. 2012 Apr 1;30(10):1107-13. doi: 10.1200/JCO.2011.38.6979. Epub 2012 Feb 27.
3
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
4
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].随机 III 期试验：二线吉西他滨和紫杉醇化疗治疗晚期膀胱癌患者：短期与长期治疗的比较[德国泌尿肿瘤学会（AUO）试验 AB 20/99]。
Ann Oncol. 2011 Feb;22(2):288-94. doi: 10.1093/annonc/mdq398. Epub 2010 Aug 2.
5
Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.晚期尿路上皮癌患者是否从每周紫杉醇化疗中获益？GETUG Ⅱ期研究。
Clin Genitourin Cancer. 2009 Aug;7(2):E28-33. doi: 10.3816/CGC.2009.n.018.
6
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.在接受含铂方案治疗后的晚期尿路上皮移行细胞癌患者中，长春氟宁联合最佳支持治疗与单纯最佳支持治疗的III期试验。
J Clin Oncol. 2009 Sep 20;27(27):4454-61. doi: 10.1200/JCO.2008.20.5534. Epub 2009 Aug 17.
7
Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.吉西他滨与紫杉醇联合用于晚期尿路上皮癌的二线化疗。
Jpn J Clin Oncol. 2009 Apr;39(4):244-50. doi: 10.1093/jjco/hyp003. Epub 2009 Feb 10.
8
Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer.中性粒细胞/淋巴细胞比值及其与非小细胞肺癌完全切除术后生存率的关系。
J Thorac Cardiovasc Surg. 2009 Feb;137(2):425-8. doi: 10.1016/j.jtcvs.2008.05.046. Epub 2008 Aug 29.
9
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.晚期胃癌患者中性粒细胞与淋巴细胞的基线比值与患者预后相关。
Oncology. 2007;73(3-4):215-20. doi: 10.1159/000127412. Epub 2008 Apr 17.
10
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.上皮性卵巢癌患者治疗前的中性粒细胞与淋巴细胞比值升高，且可预测治疗后的生存率。
Cancer Immunol Immunother. 2009 Jan;58(1):15-23. doi: 10.1007/s00262-008-0516-3. Epub 2008 Apr 15.
Zotero 插件